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Desirable cells for human cell therapy would be ones that can be generated by simple isolation and culture
techniques using a donor sample obtained by non-invasive methods. To date, the different donor-specific cells that
can be isolated from blood, skin, and hair require invasive methods for sample isolation and incorporate complex
and costly reagents to culture. These cells also take considerable time for their in-vitro isolation and expansion.
Previous studies suggest that donor-derived cells, namely urine stem cells and renal cells, may be isolated from
human urine samples using a cost-effective and simple method of isolation, incorporating not such complex
reagents. Moreover, the isolated cells, particularly urine stem cells, are superior to conventional stem cell sources in
terms of favourable gene profile and inherent multipotent potential. Transdifferentiation or differentiation of human
urine-derived cells can generate desirable cells for regenerative therapy. In this review, we intended to discuss the
characteristics and therapeutic applications of urine-derived cells for human cell therapy. Conclusively, with detailed
study and optimisation, urine-derived cells have a prospective future to generate functional lineage-specific cells for
patients from a clinical translation point of view.
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Cell therapy aims to restore diseased or injured tissues
by replacing lost cells with functional cells to
re-establish normal function [1]. Generally, functional
cells for therapy are generated from donor-derived som-
atic cells or stem cells by differentiation. The method of
sample collection for the widely used donor-derived cells
such as keratinocytes, adipose-derived stem cells, and
mesenchymal stem cells (MSC) require needle insertion,
biopsy, or physical dislodgement by scraping. Although
these cells can be cultured and differentiated successfully
with various protocols, sample isolation is quite compli-
cated, and the cells also take considerable time for ex-
pansion. On the other hand, cells isolated from human
urine samples, urine stem cells and renal cells, do not
require such invasive methods for sample collection [2].
Urine cells can be isolated using a relatively simple
method and be expanded easily. In addition, the possibil-
ity of generating cells from urine samples makes the hu-
man urine-derived cells an attractive alternative choice* Correspondence: xin-fu.zhou@unisa.edu.au
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this article, unless otherwise stated.for cell therapy [3, 4]. However, few manuscripts have
been published thus far to describe the use of these cells
in cell therapy. In this review, we focus on some of the
significant aspects of urine cells that can be utilised for
different patient-specific regenerative therapies.Isolation of urine-derived cells
The ease of isolation is the main advantage of urine-
derived cells compared with all other donor-related
samples. Adipose-derived stem cells, hair cells, and mes-
enchymal stromal cells require liposuction or invasive
methods for sample isolation. Amniotic and umbilical
cord cells are neither easily accessible nor suitable for
auto-transplantation. These hurdles make the cost of bi-
opsy for the aforementioned cells high, ranging from
$150 to 500 (per sample) and the procedure requires
hospital admission, physician consultation, and surgical
procedure. On the contrary, collection of urine samples
does not require such specialised procedures. Urine-
derived cells can be isolated at a cost less than $70 (per
sample) by simple centrifugation of the samples to sedi-
ment the cells and by seeding them onto normal culture
plates without special substrates [2]. Following isolation,
they may be expanded with minimal labour to generateAugust 2018. Open Access This article is distributed under the terms of the
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cells/100 ml sample during initial isolation which can be
expanded to 0.5–1 million by 10–15 days) that express a
wide range of markers [3].
Two significant types of undifferentiated donor-
derived cells can be generated from human urine. Firstly,
urine stem cells (USC) are progenitor cells that can be
converted into cells of multiple lineages [5]. USC sup-
posedly originate from the kidney due to their high gene
expression for kidney cortex markers [6]. Studies have
demonstrated the presence of “Y chromosome” in a fe-
male patient who received a male kidney transplant, sug-
gesting a cell origin from the kidney [6]. USC can be
expanded to generate more than a million donor specific
cells by two consecutive subcultures after their in-vitro
isolation. The second type, so called “renal epithelial
cells” or “renal cells” are considered less potent than
USC in terms of gene expression and in-vitro expand-
ability [4]. Compared with the renal cells, USC can
generate more donor-specific multipotent cells by cell
culture.
The practical method of urine cell isolation includes the
centrifugation of the collected sample at 400 g followed by
an antibacterial wash of the pellets (to avoid contamin-
ation) and later seeding them onto culture plates with
medium. For USC, the sedimented cells are seeded and
subcultured with 10% fetal bovine serum containing Dul-
becco’s modified Eagle’s medium (DMEM), DMEM/nutri-
ent mixture F-12 (DMEM/F-12) and keratinocyte
serum-free medium with supplements. USC can be pre-
served inside the collected urine samples for 24 h without
any considerable loss of viability [7]. USC have been iso-
lated from patients with a number of disease conditions
including haemophilia A, B-thalassemia, Duchenne mus-
cular dystrophy, systemic lupus erythematosus, epidermo-
lysis bullosa, bladder cancer, and neurological disorders
(Parkinson’s disease, acute myeloid leukaemia) [8–12].
Renal cells have been isolated from healthy donors only,
and thus less information is available on the isolation of
renal cells from diseased patients. Unlike USC, renal cells
are seeded and cultured using renal epithelial cell growth
medium. After isolation and expansion and preservation
using dimethyl sulphoxide, USC and renal cells can be
stored in liquid nitrogen, holding a strong revival capabil-
ity for future applications without any considerable loss of
viability [8].
Podocytes and proximal tubule epithelial cells (PTEC)
are the other two types of cells that can be isolated from
human urine samples. However, podocytes and PTEC are
mature, differentiated cells and have less expandability
and lifespan compared with the undifferentiated cells
(USC and renal cells) that can be isolated from urine
samples. In addition, the cells require immortalisation to
maintain them in vitro. Because of the terminaldifferentiation, podocytes and PTEC are non-significant in
terms of generating lineage-specific cells in considerable
quantities for therapy and therefore are not discussed in
this review.
Characteristics of urine-derived cells
Urine stem cells (USC)
Urine stem cells (USC) express a variety of markers for
pericyte, MSC, and pluripotent stem cell markers (Table 1).
Some of the key pericyte markers expressed by USC are
CD224, CD146, platelet-derived growth factor r beta
(PDGF-rβ), and neural/glial antigen 2 (NG2). The critical
MSC markers such as CD44, CD73, CD90, and CD105
are highly expressed by USC. Previous studies suggest that
USC are urine-derived MSC due to the high expression of
the above markers [13]. In addition, USC express the
pluripotent stem cell markers POU5F1 or octamer-
binding transcription factor 3/4 (Oct 3/4), VMyc avian
myelocytomatosis viral oncogene homologue (c-Myc),
stage-specific embryonic antigen 1/4 (SSEA-1/4), and
Kruppel-like factor 4 (Klf-4) [5]. Since urine contains dif-
ferent cell types, after sample isolation the aforementioned
pluripotent marker expressions can serve as typical
markers for the confirmation of USC isolation from any
donor sample. In addition, USC express the renal cortex
markers sine oculis homeobox homologue 2 (SIX2),
neural cell adhesion molecule (NCAM), epithelial cell ad-
hesion molecule (ep-CAM), and frizzled class receptor
(FZD), suggesting their origin from the kidney [14–16].
Therefore, urine-derived stem cells may also be termed
kidney progenitor cells or kidney stem cells [17]. Urine
stem cells also express a small proportion of endothelial,
epithelial, smooth muscle, and interstitial markers (Table
1), and the significant highlight of these cells is their high
in-vitro expandability.
USC have high expandability compared with other
widely used stem cells such as bone marrow stem cells,
blood progenitor cells, keratinocyte progenitor cells, um-
bilical cord stem cells or adipose-derived stem cells [18–
21]. Urine stem cells may reach nearly 70 population
doublings and have an average doubling time of 21–
24 h. On the other hand, the doubling time of the afore-
mentioned non-urine-derived cells are greater than 24 h
and their method of isolation and culture incur consid-
erable time as it involves complicated methods of sample
processing. USC isolation does not involve such compli-
cated procedures for sample processing. Furthermore,
with the addition of serum-containing medium, more
USC were cultured from one sample. Interestingly,
Schosserer et al. reported that the USC isolation
efficiency of male donors is better than female donors
[22]. An important matter that requires attention here is
the significant variability of gene expression in the
isolated USC. A recent study on USC has demonstrated
Table 1 Markers expressed by different urine-derived cells
Markers Urine stem cells Renal cells Podocytes PTEC Reference
ESC/iPSC Oct 3/4, Sox-2, c-Myc, Klf-4,
SSEA-4, Tra-1-60, Tra-1-81
Sox-2 – – [3, 6]
MSC CD29, CD44, CD54, CD73,
CD90, CD105, CD166, STRO-1
– – – [13]
Pericyte CD24, CD133. CD140b, CD146, CD224,
PDGF-rβ, NG-2
– – – [46]
Haematopoietic
stem cell
CD34, CD45, MHC-I – – – [13]
Interstitial cells c-Kit – – – [3]
Renal tubular CK-7 CK-7, SLC2A1 – – [32]
Fibroblasts Vimentin, α-tubulin Actin, Vimentin – – [32]
Smooth muscle α- SMA, Desmin – – – [6]
Urothelial CK-13, CK-19, Uroplakin CD 13 – – [46]
Endothelial vWF, CD31 – – – [27, 47]
Kidney-specific Pax 2, Pax 8, Six 2, FZD,
ep-CAM
L1CAM, NR3C2 – – [32, 46]
Membrane/tight
junction
Zo-1, Occludin (traces) β- Catenin, E-cadherin,
Claudin 1
– Zo-1, E-cadherin, MRP4
Oct-2 P-gp, BCRP
[32, 86]
Pancreatic – Sox-17, PDX1 – [55]
Hepatic – Sox-17, AFP – [55]
Others Podocalyxin, synaptopodin,
GLEPP1, podocin
Collagen I αI, Collagen IV
αI, fibronectin I, laminin 5
[86, 87]
Urinary stem cells (USC) stand superior in terms of the markers expressed. The gene profile of renal cells has not been extensively studied compared with USC
and, therefore, detailed analysis of the markers needs to be carried out
See the abbreviations list for definitions of the marker acronyms
ESC embryonic stem cells, iPSC induced pluripotent stem cells, MSC mesenchymal stem cells, PTEC proximal tubule epithelial cells
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culturing [23]. Regardless, the cells maintain their multi-
potent nature in vitro.
Similar to induced pluripotent stem cells (iPSC), em-
bryonic stem cells (ESC), and MSC, USC are multipo-
tent [12, 24]. USC have shown the capability to generate
cells from the mesoderm, endoderm, and ectoderm. Fur-
thermore, USC secrete 25 different angiogenic paracrine
growth factors as detected by human angiogenesis array,
which include the key angiogenic factors such as vascu-
lar endothelial growth factor (VEGF), fibroblast growth
factor (FGF), insulin growth factor (IGF), hepatocyte
growth factor (HGF), platelet-derived growth factor
(PDGF), and matrix metalloproteinases (MMP) [24, 25].
These angiogenic and immunomodulatory growth fac-
tors may play an important role in the vascularisation of
cells derived from USC which, if subsequently trans-
planted, might influence the immune system of the
hosts. Supplementation of the endogenous VEGF pro-
duction of USC with growth factor beads have improved
angiogenesis and stress urinary incontinence (SUI) in ro-
dents by increasing vascularisation and survival of the
transplanted cells [24, 26]. In addition, USC have im-
proved the in-vivo vascularisation and growth if deliv-
ered through hydrogels, collagen, alginate microbeads,or three-dimensional biofilms in mice [24, 26–30]. The
stem cells have restored sphincter function after vaginal
distension injury in rats [31]. Thus urine-derived stem
cells have great potential to generate donor-specific au-
tologous cells for tissue repair for multiple degenerative
diseases (Table 2).
Renal cells
Renal cells are considered as intermediate cells between
kidney proximal tubular epithelial cells and fibroblasts
(Table 1). Research indicates that renal cells express
Beta-cadherin, E-cadherin, CD13, cytokeratin 7, zona oc-
cludens 1 (Zo-1), fibronectin, and vimentin [32]. They
express some neuronal, beta cell, and hepatocyte
markers (Table 1). The cell growth and in-vitro charac-
teristics of renal cells are not known extensively in com-
parison with urine stem cells. However, from our
in-vitro expansion studies of renal cells and USC, the
isolated renal cells demonstrated less expandability than
urine stem cells (Fig. 1). Nevertheless, irrespective of the
donor sample and volume, urine stem cells demon-
strated an in-vitro lifespan of approximately 40–45 days
(Fig. 1). Renal cells derived from human urine samples
were converted into neural stem cells by a non-
integration-free method using small molecules [33]. The



















Uroepithelial Uroplakin Ia Uroplakin-III, AE1/AE3 and
CK7
Yes Urological reconstruction [3, 6]
Smooth muscle α-SMA Desmin, Myosin, Smoothelin, Yes Bladder reconstruction,
Genitourinary repair
[5, 14]
Myogenic Nil MyoD, Myogenin, Myf5,
Myosin
Yes Heart repair, SUI [88, 89]
Beta–like cells Nil PDX1 Yes Diabetic treatment [62]
Osteogenic Nil Osteocalcin, Runx2, ALP Yes Bone tissue engineering [21]
Neuronal Sox-2 GFAP, Nestin, NF-200, S100 no Neural tissue engineering [85]
Chondrogenic Nil Sox-9, Collagen II, Aggrecan Yes Cartilage replacement [22, 90]
iPSC Klf-4, Sox-2, Oct 3/4,
c-Myc
Nanog Yes (teratoma) Disease modelling/drug
screening
[91]
Renal cells Neural stem cells Sox-2 Nestin, Pax6, Yes Neurodegenerative disorders [33]
Beta cells Sox-17, PDX1 NKX6.1, Insulin, C-peptide Yes Diabetic therapy [55]
iPSC Unknown Sox-2, Oct3/4, Klf-4, Tra-1,
SSEA-4
Yes (teratoma) Disease modelling/drug
screening
[32]
Urine stem cells have been shown to generate differentiated cells for kidney, genitourinary, cartilage, bone, and cardiac repair
Renal cells have been utilised to generate differentiated cells such as beta cell and liver cells
Pluripotent stem cells have been generated from both renal cells and urine stem cells
See the abbreviations list for definitions of the marker acronyms
iPSC induced pluripotent stem cells, SUI stress urinary incontinence
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three different brain cell types (astrocytes, oligodendro-
cytes, and neurons), providing a safe and promising op-
tion for neurodegenerative diseases. In addition, the
protocol does not incorporate any transcription factors
and does not cause potential alterations in the genome.
From our research, we have found out that the renal
cells express the sex-determining region Y-related HMG
box (Sox)-17 marker at high levels (Fig. 2), suggesting
that they can be useful for generating endoderm-derived
cells. Due to the high expression of the key endoderm
marker Sox-17, renal cells can be a good source of
donor-specific cells for liver, pancreas, or thyroid repair.
However, extensive studies should be carried out on
renal cells, as with USC, to understand their potential in
terms of differentiation, gene expression, paracrine activ-
ity, and transplantation.
Above all, renal cells and USC can serve as the easiest
cells to be isolated from any other well-studied donor
cells and, consequently, urine-derived cells can serve as
an ideal choice for generating differentiated cells for hu-
man therapy (Table 1).
Therapeutic applications of urine-derived cells
Currently there is a lack of robust donor-derived cells
that can serve as potent therapeutic cells for humantherapy. Nevertheless, human therapy requires millions
of cells ready for transplantation [34]. Hence, the choice
of precursor cells is a significant challenge to achieve the
cell numbers required for transplantation [18, 35]. In
addition, the cells to be utilised for regenerative therapy
have to meet other general stem cell characteristics.
They should be harvested non-invasively from the donor
and should be differentiated into multiple lineage cells
in a reproducible manner. Moreover, the cells must be
safe to perform an autologous transplant and should be
generated according to Good Manufacturing Practise
(GMP) guidelines. Urine cells also have other possible
advantages from a therapy prospective. The ease of
donor sample collection with minimal ethical issues
makes them ideal for clinical applications. In addition,
the low costs and the simple method of cell isolation is
another advantage. Furthermore, there should be no im-
mune rejection if used for regenerative transplants and
it can be straightforwardly automated. Above all, the
cells can be translated into commercial production and
widespread clinical applications [3, 4, 6, 19, 20]. For the
mass production of a wide range of differentiated cells
(Table 2), urine-derived cells can serve as autologous cell
therapy for erectile dysfunction, SUI, kidney bioengin-
eering, cardiac and genitourinary repair, liver reconstruc-
tion, and neurodegenerative disorder treatment [2, 21,
Fig. 1 In-vitro characteristics of the urine-derived cells. a Growth curve analysis of renal cells (RC) and urine stem cells (USC) from different
donors. Analysis reveals that USC have better expandability than renal cells. Renal cells demonstrated less expandability by passage 5. RC M60,
M43, F38, and M37 indicate cells cultured from donors of the following ages (years)/gender: 60 (male), 43 (male), 38 (female), and 37 (male),
respectively. C1 and C2 indicates the cell line number. USC M22, M28, F29, and M63 indicate urine stem cells cultured from donors of the
following ages (years)/gender: 22 (male), 28 (male), 29 (female), and 60 (male), respectively. b Life-span of urine stem cells. Irrespective of the cells
being from different donors, the isolated urine stem cells have been shown to generate viable cells up to 40–45 days
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treatment of these diseases are generated from iPSC.
However, extensive differentiation protocols combined
with ethical issues makes iPSC more complicated for use
in clinics.
Renal reconstruction/kidney bioengineering
Generally, organ-specific cells are considered ideal for
the treatment of the organ from which they are isolated
or originate [39]. For this reason, urine stem cells will be
the best option for genitourinary repair and kidney bio-
engineering. Urine cells have the potential to be differen-
tiated into smooth muscle, myocytes, epithelial, and
endothelial cells that forms most of the renal tissues.
Three-dimensional arrangement of these cells can lead
to the development of a kidney-like structure that can
successfully function.
Presently, the concept of bioartificial kidneys are gain-
ing popularity in terms of treating kidney failure. How-
ever, the cells used inside the device need to be effective
in terms of removing the uremic toxins and to perform
the complex glomerular functions [40]. Epithelial cells
from the proximal tubule-derived cells are generally
used for these devices [41]. USC and renal cells can
serve as a good replacement for epithelial and proximal
tubule cells in the bioartificial kidneys. In addition toepithelial and proximal tubule cells, endothelial and
MSC have also been proven effective for reducing the
progression of chronic kidney diseases in clinical trials
[42, 43]. The transplanted cells have been shown to re-
duce inflammation, oxidative stress, and tubular injury
via the release of cytokines and growth factors, thereby
reducing the development and intensity of the disease
[44, 45]. When combined with growth factors and deliv-
ered through biopolymers, urine stem cells have also
shown to release similar cytokines (IGF and VEGF) and
increase the vascularisation by angiogenesis, suggesting
their promising future for treating kidney diseases [27].
As the kidney is a complex organ of 26 heterogeneous
tissues, whether the differentiated urine cells can main-
tain functionality similar to the kidney requires extensive
research.
Genitourinary repair
Urine cells can be easily cultured and transplanted (with
or without differentiation to endothelial cells) for genito-
urinary repair [46]. The endothelial cells expressed the key
markers kinase insert domain receptor (KDR), vascular
endothelial (VE)-cadherin, Fms-like tyrosine kinase 1
(FLT-1), and endothelial nitric oxide synthase (eNOS),
suggesting functional properties of the differentiated urine
cells. Research suggests that differentiated endothelial cells
Fig. 2 Sox-17 expression in renal cells. a RC F38, b RC M37, and c RC M43 indicate renal cells cultured from donors of the following ages (years)/
genders: 38 (female), 37 (male), and 38 (male), respectively. The blue colour indicates nuclear staining of individual cells for all Sox-17 staining for
respective donors. Depending on the quality of samples, the cells were positive for the endoderm marker Sox-17 (red colour) at varying levels.
For the phase-contrast images, pictures were taken at 4× magnification and scale bar = 1000 μm. For fluorescent images, pictures were taken at
40× magnification and scale bar = 50 μm
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treat end-stage bladder diseases or bladder pain syndrome
[3, 47, 48]. Transfected urine cells with epithelium-derived
factor as well as differentiated uroepithelial cells were
proven to minimise erectile dysfunction and corrected the
cavernous structure by nerve regeneration in rodents [49].
In addition, the skeletal progenitors differentiated from
USC can be used to treat SUI patients for muscle regener-
ation [46]. The urothelial and skeletal differentiation in-
duced the expression of uroplakin-III, the anion exchange
proteins AE1 and AE3, cytokeratin (CK)7, and desmin,
myosin, and smoothelin [6]. The significant challenge
using urine cells in a reconstructive scenario will be if the
cells are strong enough to withstand the urinary pressure
and layered structure while maintaining functionality.
Again, this is a combined effort between the cells and the
biomaterial used for urinary conduits, and functional stud-
ies need to be carried out. However, biomaterials or scaf-
folds containing smooth muscle cells and urothelial cellsdifferentiated from USC can be promising conduits for
urinary reconstruction [46, 50].
Cardiac repair
Heart failure mainly involves damage of the heart muscle
leading to its improper functioning [51]. Currently, iPSC
and ESC have been shown to generate cardiomyocytes
by differentiation [52, 53]. Pluripotent cells are hard to
obtain and take an extensive time for differentiation.
Urine cells are easy to obtain and to differentiate in vitro
[6]. Differentiated myocytes from urine cells have shown
augmented expression of myofibrillar proteins and sur-
face markers such as myogenic differentiation (MyoD)
factor, myogenin, and myogenic factor 5 (Myf5) (Table
2) [6]. However, no further research has been carried out
in terms of optimising the method to generate functional
cardiomyocytes from USC. With proper differentiation
and further screening of molecules, they can be further
differentiated into considerable quantities of contractile
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heart damage.
Liver reconstruction
A large percentage of the human population has been af-
fected by liver failure globally, and almost all cases re-
quire organ transplantation [54]. In cases of acute liver
failure, transplantation is the only option. Due to donor
tissue insufficiency or immunogenicity of the trans-
planted liver cells, most patients die. A possible alterna-
tive for transplantation is to provide patient-specific
hepatocytes. Renal cells have already been transdifferen-
tiated into insulin-secreting cells by small molecules
[55]. Efficient transdifferentiation will be achieved if the
parent cell used for transdifferentiation belongs to the
same germ layer as the transdifferentiated cell [54]. As
renal cells have high expression of the endoderm marker
Sox-17 (Fig. 1), the transdifferentiation process to gener-
ate endoderm-derived cells (thyroid cells, liver cells, and
pancreas) from the urine cells will be easy and efficient
as both the renal cells (parental cells) and transdifferen-
tiated (final) cells will share the same pedigree. There-
fore, with proper screening of small molecules and
further analysis, urine cells can be transdifferentiated
into hepatocytes. Besides, the isolated urine cells behave
like mesenchymal cells and MSC are highly flexible in
generating hepatocytes in vitro [56–58].
Diabetes treatment
Diabetes has become the fastest growing chronic condi-
tion, with the incidence increasing at a higher rate than
other chronic conditions such as heart disease and can-
cer. By 2020, the World Health Organization (WHO)
has envisioned that 380 million people will be affected
with this disastrous disease [59]. Although islet trans-
plantation has been carried out in patients using cells
from cadavers, the quantity of cells required is not suffi-
cient. They also require life-long immune suppression
for graft survival in the receivers [60]. Current beta-cell
transplantation requires a large number of cells (10,000
islet equivalent/kg of body weight) for successful re-
placement [61]. Using urine cells these numbers are
achievable, and research also suggests that the renal cells
can be efficiently differentiated into insulin-secreting
cells by small molecules [55]. A single study involving
urine cells has reported an efficient protocol to generate
functional insulin-secreting cells from renal cells [55].
The cells express PDX1+ve/NKX6.1+ve/INS+ve and ex-
hibit glucose-stimulated insulin secretion. In another
study, after transplantation undifferentiated urine stem
cells were able to generate pancreatic and duodenal
homeobox 1 (PDX1)-positive cells in vivo and to minim-
ise the disease symptoms [62]. Surprisingly, the re-
searchers used USC isolated from healthy individualsonly for the study. A similar study needs to be per-
formed using the urine cells isolated from urine samples
of diabetic patients. This will also address the question
whether there are considerable differences in the isola-
tion efficiency, morphology, and gene expression of
markers in cells isolated from diabetic patients, critical
for developing the idea towards clinical application.
Nevertheless, sample collection combined with minimal
effort for culture, followed by efficient conversion into
insulin-secreting beta cells for transplantation from
urine cells can bring revolutionary changes in the field
of diabetes treatment.
Neuroregeneration
Clinical trials using stem cell-derived neurons for brain
disorders are limited. Several studies have reported the
generation of functional neurons from the in-vitro differ-
entiation of pluripotent stem cells or neural stem cells
[63–65]. However, pluripotent stem cell-based protocols
take nearly 2 months to generate functional neuronal
cells [66, 67]. In addition, after in vivo transplantation,
the cells lose their functionality due to the damage in
the complex dendritic structure after separating them
from the in-vitro adherent culture. An alternative option
is to generate immature cells capable of efficient matur-
ation after transplantation. Urine stem cells treated with
growth factors and cultured on laminin-treated plates
have been reported to show efficient conversion into im-
mature neuronal cells [68, 69]. Donor-specific immature
cells grown in biomaterials such as hydrogels can be
transplanted without much loss of structure and can fur-
ther facilitate the integration and maturation of the cells
in vivo. In addition, Cheng et al. formulated a small mol-
ecule cocktail to generate neural progenitor cells from
renal cells which show functional properties in vitro
(Sox2+ve/Pax6+ve cells, alkaline phosphatase staining,
electrophysiology recordings) and in vivo (transplant-
ation and survival) [33]. This may well serve as a pos-
sible alternative to provide functional neurons in larger
quantities without any considerable loss of cells during
transplantation for neuroregenerative therapy. Again, the
critical part of using the technology will be to generate
specific types of neurons (for example, dopaminergic
neurons for Parkinson’s disease) within the biomaterials.
However, formulating a standardised protocol for USC
differentiation within the biomaterial with a reliable out-
come is challenging, but feasible.
Bone engineering
Osteoblast grafts can be used as an effective solution for
bone regeneration [70]. A human source of autologous
cells in large numbers that can differentiate or can be
differentiated into osteoblasts is critically important for
engineering human bone grafts [70, 71]. However,
Pavathuparambil Abdul Manaph et al. Stem Cell Research & Therapy  (2018) 9:189 Page 8 of 12extensive bone damage requires osteogenic cells that can
be supplied in a three-dimensional biomaterial to
support bone regeneration. Currently, ESC- and
iPSC-derived cells are generally used for bone grafts.
Donor-derived cells such as MSC and adipose-derived
stem cells are also administered but, again, isolation of
these sources is invasive and laborious. A single recent
study involving a three-dimensional scaffold combined
with urine cells has provided convincing evidence that
the scaffold can repair critical bone defects in animals
[21]. The cells can be maintained, delivered, and effi-
ciently differentiated to provide replaceable bone cells in
damaged areas for patients and therefore could be a vi-
able option in future for orthopaedics [72]. Furthermore,
urine stem cells can serve as a better option for bone
transplants in children due to the efficient proliferative,
self-renewal, and differentiation capability of USC to
convert into osteoblasts.
Muscle engineering
The “rice grain”-like urine stem cells were transdifferen-
tiated into spindle-shaped skeletal cells on myogenic dif-
ferentiation, with high levels of expression of skeletal
muscle markers [6]. The differentiated cells continue to
proliferate and generate further skeletal cells on subcul-
ture [73]. Extensive clinical trials have been carried out
using stem cells for muscle cell therapy, and the admin-
istration of stem cells was proven to repair the damage
to some extent. Permanent repair is possible, but may
require more than one transplant using autologous,
self-renewing functional cells [74]. In addition, very few
studies have been conducted in the area of paediatric
Duchenne Muscular Dystrophy. Transplantation of dif-
ferentiated muscle cells from urine cells can be more ef-
fective than the current methods of transplantation
(from iPSC or ESC differentiation) where the cells pro-
vided are terminally differentiated without further prolif-
eration in vivo. Urine cells can not only survive but can
also proliferate moderately and generate more differenti-
ated cells than iPSC and ESC [6]. Furthermore, paediat-
ric treatment can be more effective due to the naive
nature of urine cells isolated from them [13]. Interest-
ingly, a recent study reported that urine cell generation
from new-born infants has a low efficiency of isolation
[75]. In that case, standardised protocols for isolation
and differentiation need to be established to obtain reli-
able outcomes.
Paediatric treatment
The growth of urine cells is age-dependent on the donor
sample. Studies have shown that cells isolated from
young children (not infants) have better proliferative and
differentiation capability [72]. Also, the level of expres-
sion of each marker varies during subculture of adulturine cells [23]. Due to the high expression of MSC
markers, research suggests that urine stem cells are mes-
enchymal cells derived from urine [22]. Clearly, MSC
stand out in terms of clinical trials for a number of dis-
eases [76, 77]. MSC are well known to impart minimal
immune reaction after transplantation, making them
currently the ideal source of cells for therapy. Interest-
ingly, when mixed with allogenic blood cells, USC
induced a smaller population of CD80/CD86+ cells
(surface receptor cells which activate T-cells creating an
immune reaction) compared with MSC [78]. This indi-
cates that USC have better immune tolerance and are a
very good alternative to or better than MSC for
regenerative therapy. Besides, the isolation of MSC is in-
vasive and costly [79]. Urine stem cells can be a cheap
and affordable alternative for mesenchymal cells for hu-
man therapy [13]. Also, USC have better expandability
than MSC [7]. Paediatric and adult urine can be the
ideal choice for generating a donor cell bank such as
blood, umbilical cord, or skin biopsy for future applica-
tion [13]. In fact, it will be better than any other adult
sample in terms of generating ample cells for storing
since studies have shown that the cells isolated from
young children have better proliferative and differenti-
ation capability [72]. Although urine-derived cells can
serve as donor-derived MSC, extensive pre-clinical stud-
ies in terms of gene expression, differentiation, expan-
sion, and immune reaction need to be carried out.
Nevertheless, MSC are multipotent cells that can be sub-
cultured from different sources such as blood, bone mar-
row, umbilical cord, skin, and fat [80]. Therefore, the
possibility of a subpopulation within the isolated urine
cells that exhibit the MSC characteristics is also un-
known and needs further investigation.
Disease modelling using urine-derived iPSC
iPSC have been widely used to study mechanisms of
disease pathology and to find patient-specific cures by
disease modelling [81]. Pluripotent stem cells have
proven effective in finding the underlying causes for car-
diovascular diseases (such as LEOPARD syndrome and
hypertrophy) and neurodegenerative diseases (such as
Alzheimer’s disease, schizophrenia, and amyotrophic lat-
eral sclerosis) [81]. Drug screening using differentiated
patient-specific iPSC provides better donor-specific effi-
cacy than animal-based testing, and iPSC can be effi-
ciently generated from urine samples using a volume as
low as 30 ml [32]. Research suggests that the time taken
to induce pluripotent stem cells from urine cells is
shorter (2–3 weeks) than the time taken for blood cells,
fibroblasts, or keratinocytes (3–4 weeks) [82]. This is
related to the fact that the urine cells express the pluri-
potent markers at considerable levels, which may reduce
the barrier to generate completely reprogrammed
Pavathuparambil Abdul Manaph et al. Stem Cell Research & Therapy  (2018) 9:189 Page 9 of 12pluripotent cells. Furthermore, urinary iPSC were also
derived from urine samples of patients suffering from
rare genetic disorders such as fibrodysplasia ossificans
progressive, paroxysmal kinesigenic dyskinesia, cryptor-
chism, Down syndrome, and type 2 long QT syndrome
[75], suggesting its significant prospects in studying such
rare diseases. Urinary iPSC show superior differentiation
potential and, therefore, the cells can be used for disease
modelling to understand the pathological problems re-
lated to the condition and drug screening studies for
common as well as rare genetic diseases [75, 83]. Al-
though urinary iPSC generation from urine samples of
patients is feasible and attractive compared with other
sources such as the blood, skin, and hair, some hurdles
remain, such as retaining the epigenetic memory or mu-
tation after reprogramming and performing quality test-
ing (in terms of homogeneity of iPSC clones), as well as
long-term subculture; these should be assessed before
they proceed to the clinic. Also, current exclusion cri-
teria of donor samples in clinical transplantology (chron-
ically infected human immunodeficiency virus, hepatitis
C virus, hepatitis B virus patient samples) can also make
it harder to apply urinary iPSC generation universally for
the common population.Fig. 3 Future applications of urine cells in therapy. Donor-specific urine cel
immediately or can be stored in cell banks for future revival, differentiationConclusion
Statistical analysis suggests that using the daily average
volume of urine from an individual, 10 times the num-
ber of donor-specific urine cells required for an autolo-
gous tissue repair can be generated [4]. The automation
of the urine cell cultures will make it easy to achieve the
numbers for human transplantation. As a universal sam-
ple of collection, urine-derived cells can serve as an out-
standing option for treatment of diseases such as those
in the kidney, brain and paediatrics [84]. With more ex-
tensive study, urine cells can be employed as a preserva-
tion method for patient cells to serve as a cell bank for
therapy and disease modelling study by generating iPSC
(Fig. 3) [8, 85]. In addition, urine cells can also serve as
a replacement for current MSC (derived through inva-
sive methods such as bone marrow harvest and liposuc-
tion) to generate a donor bio-bank. However, this may
require further expandability and qualitative studies, es-
pecially with the recent reports of considerable differ-
ences in isolation efficiencies and cell culture issues [23].
Although urine cells are an attractive solution, further
testing of cells (especially renal cells) needs to be con-
ducted to confirm the efficacy of the cells in terms of
functional differentiation and long-term transplantation.ls can be directly differentiated into organ-specific cells to transplant
, and transplantation. ipsc induced pluripotent stem cells
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transplantation also need to be addressed. On critical
analysis, we found significant inter-variability in the ex-
pression of reported markers and the reasons for such
variations need to be addressed. One possible explan-
ation for this heterogeneity in terms of gene expression
can be due to the mixed nature of the isolated cells. This
is also supportive of the fact that the human urine con-
tains complex constituents and cells removed from the
body. Sorting of the isolated urine cells at early passages
can minimise the variation arising from the heteroge-
neous nature of urine cell cultures. Furthermore, for iso-
lation and cell culture, we were unaware whether the
urine storage conditions after collection (including add-
ing serum to samples at room temperature and storing
at 4 °C for 24 h to perform later isolation) and the dur-
ation of time the urine is held in the bladder before col-
lection would affect the isolation. Upon extensive
review, we have found that such conditions are import-
ant; for example, previous studies have reported varia-
tions in the quality of the cells (morphology and gene
expression of USC markers) depending on different stor-
age and sample collection conditions [7, 47]. An explan-
ation is also unknown for the differences in the gene
expression of the urine cell markers in different samples
obtained from the same individual at different times
(intra-variability). Furthermore, we also need to investi-
gate if urine cell generation will be influenced by diet
and medication. Generating clinically graded autologous
cells from urine samples for cell therapy still needs com-
prehensive pre-clinical analyses to generate a standardised
procedure. Conclusively, with detailed testing and opti-
misation, urine cells can serve as the future of regenerative
therapy in terms of generating quantitative and qualitative
cells for both organ reconstruction and to understand
pathological mechanisms using disease modelling.
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